JPS60185715A - 骨形成促進剤 - Google Patents
骨形成促進剤Info
- Publication number
- JPS60185715A JPS60185715A JP4050684A JP4050684A JPS60185715A JP S60185715 A JPS60185715 A JP S60185715A JP 4050684 A JP4050684 A JP 4050684A JP 4050684 A JP4050684 A JP 4050684A JP S60185715 A JPS60185715 A JP S60185715A
- Authority
- JP
- Japan
- Prior art keywords
- lactone
- dihydroxyvitamin
- 1alpha
- accelerator
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000011164 ossification Effects 0.000 title claims description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 208000001132 Osteoporosis Diseases 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 208000005368 osteomalacia Diseases 0.000 abstract description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 2
- 229920002472 Starch Polymers 0.000 abstract description 2
- 239000001913 cellulose Substances 0.000 abstract description 2
- 229920002678 cellulose Polymers 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 239000008101 lactose Substances 0.000 abstract description 2
- 239000008107 starch Substances 0.000 abstract description 2
- 235000019698 starch Nutrition 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract 1
- 238000009833 condensation Methods 0.000 abstract 1
- 230000005494 condensation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000033444 hydroxylation Effects 0.000 abstract 1
- 238000005805 hydroxylation reaction Methods 0.000 abstract 1
- 230000030991 negative regulation of bone resorption Effects 0.000 abstract 1
- 210000000963 osteoblast Anatomy 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 208000006386 Bone Resorption Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000003455 parietal bone Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000005009 osteogenic cell Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- -1 triglyceride ester Chemical class 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- BJYLYJCXYAMOFT-RRXOBRNQSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCC(O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RRXOBRNQSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 229960002535 alfacalcidol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940090761 vitamin d and analogues Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Furan Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4050684A JPS60185715A (ja) | 1984-03-05 | 1984-03-05 | 骨形成促進剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4050684A JPS60185715A (ja) | 1984-03-05 | 1984-03-05 | 骨形成促進剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60185715A true JPS60185715A (ja) | 1985-09-21 |
| JPH0222732B2 JPH0222732B2 (enrdf_load_stackoverflow) | 1990-05-21 |
Family
ID=12582433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4050684A Granted JPS60185715A (ja) | 1984-03-05 | 1984-03-05 | 骨形成促進剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60185715A (enrdf_load_stackoverflow) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63107920A (ja) * | 1986-06-18 | 1988-05-12 | Asai Gerumaniumu Kenkyusho:Kk | 骨芽細胞活性化剤 |
| JPS6421A (en) * | 1987-02-27 | 1989-01-05 | Teijin Ltd | Preventive for osteoporosis |
| JPS6483019A (en) * | 1987-09-25 | 1989-03-28 | Sunstar Inc | Composition used in oral cavity for orthodontic therapy of tooth |
| JPH01149723A (ja) * | 1987-12-07 | 1989-06-12 | Asai Gerumaniumu Kenkyusho:Kk | 骨芽細胞活性化剤 |
| JPH03264532A (ja) * | 1990-03-15 | 1991-11-25 | Teijin Ltd | 活性型ビタミンｄ含有治療剤 |
| US5604257A (en) * | 1993-02-05 | 1997-02-18 | Teijin Limited | Lactone compound and process of production thereof |
| US5719297A (en) * | 1994-06-07 | 1998-02-17 | Teijin Limited | Vitamin D3 derivatives and production process thereof |
| JP2004075677A (ja) * | 2002-06-21 | 2004-03-11 | Toyama Chem Co Ltd | 骨欠損治療および骨損傷の治癒促進剤 |
-
1984
- 1984-03-05 JP JP4050684A patent/JPS60185715A/ja active Granted
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63107920A (ja) * | 1986-06-18 | 1988-05-12 | Asai Gerumaniumu Kenkyusho:Kk | 骨芽細胞活性化剤 |
| JPS6421A (en) * | 1987-02-27 | 1989-01-05 | Teijin Ltd | Preventive for osteoporosis |
| JPS6483019A (en) * | 1987-09-25 | 1989-03-28 | Sunstar Inc | Composition used in oral cavity for orthodontic therapy of tooth |
| JPH01149723A (ja) * | 1987-12-07 | 1989-06-12 | Asai Gerumaniumu Kenkyusho:Kk | 骨芽細胞活性化剤 |
| JPH03264532A (ja) * | 1990-03-15 | 1991-11-25 | Teijin Ltd | 活性型ビタミンｄ含有治療剤 |
| US5604257A (en) * | 1993-02-05 | 1997-02-18 | Teijin Limited | Lactone compound and process of production thereof |
| US5719297A (en) * | 1994-06-07 | 1998-02-17 | Teijin Limited | Vitamin D3 derivatives and production process thereof |
| US5986112A (en) * | 1994-06-07 | 1999-11-16 | Teijin Limited | Vitamin D3 derivative and production process thereof |
| US6177586B1 (en) | 1994-06-07 | 2001-01-23 | Teijin Limited | Vitamin D3 derivative and production process thereof |
| JP2004075677A (ja) * | 2002-06-21 | 2004-03-11 | Toyama Chem Co Ltd | 骨欠損治療および骨損傷の治癒促進剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0222732B2 (enrdf_load_stackoverflow) | 1990-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4407795A (en) | Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use | |
| US5652227A (en) | Inhibition of the degradation of connective tissue matrix protein components in mammals | |
| US3957853A (en) | Metformine salt of acetylsalicylic acid | |
| EP0504938A2 (en) | Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient | |
| EP0078599B1 (en) | Complex compounds based on cyclodextrins | |
| IL88239A0 (en) | Benzocycloheptene derivatives,their preparation and pharmaceutical compositions containing them | |
| AU6767587A (en) | Pharmaceutical compositions | |
| JPH08501546A (ja) | 骨粗鬆症治療用のプロスタグランジン類似体 | |
| US3851056A (en) | Method of depressing fatty acids and triglycerides | |
| JPH05504772A (ja) | メルカプトアシルアミノラクタムエンドペプチダーゼ阻害剤 | |
| JPS60185715A (ja) | 骨形成促進剤 | |
| DE2923009A1 (de) | Mittel zur prophylaxe und behandlung der fibrose | |
| US4578400A (en) | Therapeutic composition and method for treatment of cardiovascular diseases | |
| US4237165A (en) | Treatment of carbohydrate metabolism disorders | |
| US4097601A (en) | Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins | |
| JPH05501111A (ja) | カルボキシアルキルカルボニルアミノ酸エンドペプチダーゼ阻害剤 | |
| US3870792A (en) | Certain dihydrophthalizines for treating hemorrhage and thrombosis | |
| US4218471A (en) | Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents | |
| US4555522A (en) | Antithrombotic and/or antihypertensive compositions | |
| EP0759297A1 (en) | Remedy for pulmonary heart | |
| EP0623623B1 (en) | 2-aminoethanesulfonic acid/zinc complex | |
| JPH0959155A (ja) | コレステリルエステル転送反応阻害剤 | |
| US4402982A (en) | Antihypertension treatment and composition therefor | |
| NZ203251A (en) | Pharmaceutical compositions containing 1alpha,25,26-trihydroxycholecalciferol | |
| JPH06183958A (ja) | 骨疾患の予防・治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |